

**Title:** Total Elbow Arthroplasty: A Prospective Clinical Outcome Study of Discovery Elbow System with a 4-Year Mean Follow-Up

**Running Title:** Clinical Outcome of the Discovery Elbow

**Authors:**

1. **Dr Omid Alizadehkhayat.** Associate Professor in Health Sciences (MD, PhD). School of Health Sciences, Liverpool Hope University, Liverpool, UK
2. **Mr Ahmed Al Mandhari.** Shoulder and Elbow Fellow (MD). Upper Limb Unit, Royal Liverpool and Broadgreen University Hospitals, Liverpool, UK
3. **Dr Christos Sinopidis.** Consultant Orthopaedic Surgeon (MD, PhD). St' Lukes Hospital, Thessaloniki, Greece
4. **Ms Amanda Wood.** Research Nurse (MSc). Musculoskeletal Science Research Group, Institute of Translational Medicine, University of Liverpool, Liverpool, UK
5. **Professor Simon Frostick.** Professor of Orthopaedics (MA, DM, FRCS). Musculoskeletal Science Research Group, Institute of Translational Medicine, University of Liverpool, Liverpool, UK

**Corresponding Author:**

Professor Simon P. Frostick

Musculoskeletal Science Research Group,

Institute of Translational Medicine,

University of Liverpool

Liverpool UK, L69 3GA

Phone: +44 151 706 4120 Fax: +44 151 706 5815

Email: [s.p.frostick@liverpool.ac.uk](mailto:s.p.frostick@liverpool.ac.uk)

**Disclaimer:** Corresponding author (Professor Frostick) received royalties and consultant payments from Biomet Inc.

**Ethical Approval:** Sefton Research Ethics Committee - REC Number: 08/H1001/109

**Trust Study Number:** 3735

1 **Total Elbow Arthroplasty: A Prospective Clinical Outcome Study of Discovery Elbow**  
2 **System with a 4-Year Mean Follow-Up**

3 **Abstract**

4 **Background:** Total elbow arthroplasty (TEA) is increasingly used for the treatment of  
5 advanced elbow conditions to reduce pain and improve function. However, TEA is still  
6 associated with a higher complication rate compared to the total hip and knee arthroplasty  
7 despite advances in the design and surgical techniques. This prospective clinical study reports  
8 the outcome of the Discovery Elbow System (Biomet Inc., Warsaw IN, USA) system which  
9 has been in clinical use in the UK since 2003.

10

11 **Methods:** The study included a total of 100 Discovery elbows (April 2003 to January 2010)  
12 with a minimum 2-year follow-up including 75 primary and 25 revisions (60 % females and  
13 40% males; mean age, 62 years). Outcome was assessed by means of Liverpool Elbow Score,  
14 pain experience, patient satisfaction, range of movement, and radiographic imaging.

15

16 **Results:** Mean follow-up was 48.5 months (range: 24-108 months). Liverpool Elbow Score  
17 improved from 3.79 to 6.36 ( $P<.001$ ). Pain-free patients were substantially increased from  
18 7% preoperatively to 64% at the final follow-up. Patient satisfaction rate was over 90%. The  
19 arc of flexion-extension and pronation-supination increased from 72° to 93° and from 86° to  
20 111°, respectively ( $P<.001$ ). Major post-operative complications included deep infection  
21 (2%), progressive aseptic loosening requiring revision (primary, 5%; revision 12%),  
22 persistent ulnar neuropathy (3%), and periprosthetic fracture (primary, 6.8%; revision, 8%).

23

24 **Conclusion:** Discovery elbow resulted in improved function, reduced pain, and high patient  
25 satisfaction. Long-term results are required for assessing the survivorship of this system.

26

27 **Keywords:** Total Elbow Arthroplasty; Discovery Elbow; Clinical Outcome; Elbow  
28 Prostheses.

29 **Level of Evidence:** Level III

**30 BACKGROUND**

31 Total elbow arthroplasty (TEA) has increasingly become a popular reconstructive procedure  
32 due to improved surgical techniques, advanced implant designs, and enhanced clinical  
33 outcomes.<sup>39</sup> The modern era of TEA began in the late 1970s when the prosthetic design  
34 evolved following several key developments: the use of high-density polyethylene as a  
35 bearing surface to metal, the use of methyl methacrylate bone cement, and the  
36 implementation of biomechanical science to reproduce normal joint kinematics.<sup>7</sup> Modern  
37 TEA implants are designed as linked or unlinked. Linked implants are coupled together  
38 through a hinge allowing for some degrees of laxity in the medial, lateral, and rotational  
39 planes consistent with normal elbow kinematics. A “sloppy hinge,” design is associated with  
40 a reduced rate of aseptic loosening and instability of the articulation.<sup>34</sup> Unlinked implants are  
41 not mechanically coupled and mostly rely on matching shapes of the bearing surfaces,  
42 adequate bone stock, and, the integrity of capsular and ligamentous structures.<sup>5,7</sup> Unlinked  
43 designs have been associated with higher rate of instability as their stability mainly depends  
44 on their geometry and surrounding soft tissues (ligaments and bone stock) rather than the  
45 intrinsic constraint of the articulation.<sup>5</sup>

46

47 The use of unlinked prostheses may be preferred when there is less bone or articular  
48 destruction and in younger patients who may need later revision surgery. To the other hand,  
49 the increased stability of the linked implants has expanded their use in conditions with  
50 increased bone destruction and ligamentous incompetency such as advanced stages of  
51 rheumatoid arthritis, posttraumatic and degenerative osteoarthritis, and complex distal  
52 humerus and intra-articular fractures (particularly in elderly patients).<sup>5,7,22</sup>

53

54 Despite considerable developments in the prosthetic design, TEA has been associated with a  
55 high rate of complications, ranging from 20% to 45%, compared to other main total joint (hip

56 and knee) replacements<sup>15,27,41</sup> potentially because of the difficulty of surgical procedure in a  
57 complex joint with minimal soft tissue support.<sup>10</sup> Gschwend et al,<sup>15</sup> reviewed the literature  
58 and reported an overall complication rate of up to 43% including aseptic loosening,  
59 infections, ulnar nerve complications, instability, disassembly, dislocation, subluxation,  
60 intraoperative fractures, fractures of the prosthesis, implant loosening, periprosthetic fracture,  
61 triceps insufficiency, and ectopic bone formation. In another review, Little et al,<sup>27</sup> reported an  
62 overall complication rate of 14%-80% with a median rate of 33%.

63  
64 In terms of more specific complications, polyethylene bushing failure/wear<sup>16,25,27,34</sup> and hinge  
65 failure<sup>14, 25</sup> have been associated with the earlier designs of the linked prostheses. While  
66 linked, semiconstrained prostheses with a “sloppy” hinge linkage system were designed to  
67 protect against loosening and to allow for their use in the presence of significant bone or  
68 ligamentous deficiency;<sup>17</sup> the earlier designs have been associated with a high rate of bushing  
69 failure (14% to 47%) because of using polyethylene-type bushings which can result in  
70 particulate polyethylene-induced synovitis, osteolysis, and implant loosening.<sup>14,17,26,30,44</sup> In  
71 addition to bushing failure, other types of mechanical failures including disassembly and  
72 failure of the hinge locking mechanism have been described in relation to commonly used  
73 semiconstrained linked prostheses such as the Coonrad-Morrey<sup>12,37,44</sup> and GSBIII.<sup>15</sup>

74  
75 The Discovery™ Elbow System (Biomet Inc, Warsaw, IN, USA) was designed to address  
76 specific complications associated with the earlier designs by providing more accurate  
77 positioning of the elbow flexion/extension axis; ensuring stability without employing a true  
78 hinge; distributing contact forces over large condylar surfaces; and preserving the ulnar  
79 collateral ligament.<sup>17,18</sup> Furthermore, assembling chrome cobalt condyles that connect the  
80 humeral and ulnar components after cementing preserves the humeral condyles. These design  
81 characteristics is expected to reduce the rate of polyethylene bushing wear, reinforce  
82 anatomic stem design, restore natural elbow joint biomechanics, and produce a hinge that

83 could be easily revised.<sup>17</sup> The Discovery elbow has been in clinical use in the UK since 2003.  
84 The structural specifications and design rationale of the system have been described in full  
85 details by Hastings and Theng<sup>19</sup> and Hastings.<sup>17</sup>  
86  
87 This study aimed to 1) report functional and radiological outcome of the Discovery elbow in  
88 a large series of primary and revision TEAs with various elbow pathologies; and 2) compare  
89 the clinical outcome and complications with published literature on other prostheses.

**90 PATIENTS AND METHODS**

91 One hundred Discovery elbows with a minimum 2-year follow-up were included in the study.  
92 All TEAs were performed in a single centre by the same surgeon (April 2003 to January  
93 2010). The technical properties of the prosthetic system and surgical technique have been  
94 described in full details by Hastings et al.<sup>17</sup>

95 The mean age of patients (females, 60 %; males, 40%) was 62 years (range: 22-86), weight  
96 71.8kg ( $\pm$ 18.3), and height 166 ( $\pm$ 12.5). The mean follow-up period was 48.5 months (range:  
97 24-108 months). Inclusion criteria were advanced arthritis unresponsive to non-operative  
98 management, acute distal humerus fracture and revision for loosening of other elbow  
99 prostheses in skeletally mature patients (>18 years old). Exclusion criteria included  
100 systematic metabolic diseases affecting the bone formation and active infection. The main  
101 underlying pathologies (diagnoses) are outlined in Table1. Primary and revision TEA  
102 comprised 75% and 25% of the cases, respectively. Study received approval from a local  
103 research ethics committee and all patients gave informed consent prior to the surgery.

104

**105 FOLLOW UP ASSESSMENT****106 Functional Outcome**

107 Main clinical information and data including underlying pathology (primary diagnosis), type  
108 of TEA (primary, revision), follow-up period, pain experience ('No Pain', 'Mild Pain',  
109 'Moderate Pain', 'Severe Pain'), patient satisfaction ('Not Satisfied', 'Satisfied', 'Somewhat  
110 Satisfied', 'Very Satisfied'), range of movement (flexion/extension of the elbow and  
111 pronation/supination of the forearm), and complications were collected using a purpose-  
112 designed elbow arthroplasty proforma. A validated elbow-specific score, Liverpool Elbow  
113 Score (LES), was used for functional assessment (Appendix1).<sup>35,42</sup> The patient-rated section  
114 of the LES has good correlation to the Mayo Elbow Performance Score (MEPS) and has been

115 recommended as an outcome measure for evaluating the results of TEA.<sup>4</sup> The AO handbook  
116 for Musculoskeletal Outcomes Measures and Instruments rated this score as a superior  
117 quality outcome assessment tool compared to MEPS.<sup>39</sup> A score of 0 and 10 indicate worst  
118 and best outcome, respectively.

119

#### 120 Radiographic assessment

121 Radiographic assessment involved preoperative and post-operative (immediately post-  
122 operative; 3, 6, 12 months post-operative; and then annual) anteroposterior and lateral plain  
123 x-rays (Figure.1). Imaging was reviewed for humeral and ulnar stem alignment in sagittal and  
124 coronal planes, aseptic loosening, periprosthetic fracture, dislocation, and hypertrophic  
125 ossification. Imaging assessment pattern followed the principles explained in a recent  
126 comprehensive radiographic review of TEA.<sup>31</sup> For assessing the component alignment, angles  
127 between the axis of the shaft of humerus and the stem of the humeral component and between  
128 the axis of the shaft of ulna bone and the stem of the ulnar component were measured in the  
129 early post- operative x-rays.<sup>13</sup> A malalignment of  $>10^\circ$  was considered as significant.<sup>11,13,40</sup>  
130 Periprosthetic fracture was evaluated based on Mayo Classification System (Figure.2).<sup>30</sup>  
131 Radiographic and clinical assessments were performed by independent assessors other than  
132 the principal surgeon to eliminate the possibility of information bias.

133

#### 134 Data Analysis

135 Continuous and descriptive data are reported as mean and standard deviation (Mean  $\pm$  SD)  
136 and 95% confidence interval. Categorical data are described using proportion and percentage.  
137 Paired Student *t* test or ANOVA were used to compare the preoperative LES and ROM with  
138 those at the final follow-up for the entire patient group and according to underlying pathology  
139 (primary diagnosis) and type of TER (primary, revision), as appropriate. The level of

140 significance was set at 5 % ( $p < 0.05$ ). SPSS package (IBM SPSS Statistics for Windows,  
141 Version 21.0. Armonk, NY: IBM Corp.) was used for data analysis.



## 142 **RESULTS**

### 143 **Functional Outcome Results**

144 Preoperatively, 61% and 21% of patients experienced severe and moderate pain, respectively  
145 which was then reduced to 11% and 14% post-operatively. The percentage of pain-free  
146 patients was substantially increased from 7% preoperatively to 64% at the final post-  
147 operative follow-up. In terms of patient satisfaction, 63%, 8%, and 23% of patients were  
148 classified as 'Very Satisfied', 'Somewhat Satisfied', and 'Satisfied', respectively. Only 6%  
149 (primary, 5%; revision, 1%) remained unsatisfied with the outcome.

150

151 The mean preoperative and final follow-up LES were 3.79 ( $\pm 1.71$ ) and 6.36 ( $\pm 1.85$ ),  
152 respectively which highlighted a significant improvement ( $p < 0.001$ ). Similar improvements  
153 were observed for all main pathology groups (inflammatory and non-inflammatory arthritis,  
154 and Fracture), however, LES improvement was significantly higher in the primary ( $6.41 \pm 17$ )  
155 compared to revision TEA ( $5.78 \pm 14$ ) ( $p < 0.05$ ). Table 2 summarises the results of ROM for  
156 flexion and extension of the elbow and pronation and supination of the forearm for entire  
157 patient group and according to the main diagnoses. **A significant improvement was noted for  
158 all measured movements except elbow extension (extension deficit). Despite lack of  
159 improvement in the mean elbow extension, flexion-extension arc was significantly improved.  
160 ROM improvements in revision TEA were comparable with those of primary TEA.**

### 161 **Radiographic Assessment Results**

162 Pre-operative and post-operative follow-up (immediately post-op; 3, 6, 12 months post-op;  
163 annual, and the final follow-up) x-rays of 88 TEAs (88%) (primary, 70; revision, 18) were  
164 available for review. Table 3 presents the degree of alignment of humeral and ulnar  
165 components (stems) in both sagittal and coronal planes. Around 90% of the evaluated TEAs  
166 presented with a good alignment ( $< 5^\circ$ ) for both components in both planes. A significant

167 malalignment ( $>10^\circ$ ) was seen in one primary TEA elbow; however it was not associated  
168 with early loosening.

169 The overall incidence of periprosthetic fracture was 14.8% (primary, 6.8%; revision, 8%)  
170 involving humeral condyles and olecranon in 9.1% and 5.7% of elbows, respectively. All  
171 fractures were classified as Mayo Type 1 and managed conservatively. Hypertrophic  
172 ossification occurred in 6.8% of TEAs (primary, 5.7%; revision, 1.1%). Areas of non-  
173 progressive lucency were noted around the bone-cement interface of 10 primary and seven  
174 revision TEAs without any further progression.

### 175 **Marked Complications**

176 **Marked complications including deep infection, osteolysis/loosening, prosthetic failure, and**  
177 **permanent ulnar neuropathy occurred in approximately 16% of TEAs of which 13% required**  
178 **further surgical management. Marked osteolysis around the humeral component was**  
179 **observed in two of primary and one of revision TEAs; but the prosthesis remained stable with**  
180 **no need for revision. Four primary TEAs developed significant osteolysis and required**  
181 **revision of either humeral component (n=3) or both humeral and ulnar components (n=1).**  
182 **Three revision TEAs developed progressive loosening of both humeral and ulnar**  
183 **components; two underwent 2nd revision and one is awaiting revision. Deep infection**  
184 **occurred in 2 cases (both required a 2-stage revision), persistent ulnar neuropathy in 3 cases**  
185 **(managed with nerve decompression and transposition), and prosthetic failure in 1 case. The**  
186 **prosthetic failure was of non-traumatic nature and occurred due to the failure of the screws at**  
187 **the linkage mechanism causing the dissociation of the condyle from main components. This**  
188 **prosthetic failure was managed by revision surgery and change of the screws. The cause of**  
189 **this failure was believed to be related to the primary design of the prosthesis which was later**  
190 **improved.**

191 **DISCUSSION**

192 Despite recent developments in the design of elbow prostheses, advances in surgical  
193 techniques, and marked improvements in pain and function, TEA is still associated with high  
194 complication and revision rates compared to hip and knee arthroplasty.<sup>7,41,43</sup> This high  
195 complication rate is partly related to the anatomical characteristics of the elbow such as  
196 insufficient bone stock for implantation and lack of strong supporting soft tissue.<sup>3,24</sup>

197  
198 Elbow prostheses have been used for decades in linked (e.g. Coonrad-Morrey, GSB III,  
199 Triaxial, Discovery System) and unlinked (e.g. Kudo, Souter-Strathclyde, IBP) or both linked  
200 and unlinked (e.g. Acclaim) modes. The Discovery elbow is a linked prosthesis with a design  
201 that mimics the anatomical characteristics and kinematics of the elbow joint. The present  
202 study reports the clinical outcome of TEA with this system over a 4-year mean follow-up and  
203 compares the results with other reports. However, direct comparison of clinical outcomes  
204 amongst different TEA implants is a challenging task because of heterogeneity in reporting  
205 methods of function, pain experience, patient satisfaction, and radiographic assessment.

206  
207 Pain relief is one of the prime benefits following any joint arthroplasty. In the present study,  
208 around 64% of cases had no pain at the final follow-up. The majority of the studies on TEA  
209 have used percentage of patients with no pain or mild pain as measure of success of the  
210 procedure. By that standard, 78% of our cases had either no pain or only mild pain at final  
211 follow-up. The percentage of patients with no pain or mild pain after undergoing Acclaim,<sup>6</sup>  
212 Souter-Strathclyde,<sup>33</sup> GSB III<sup>15,23,36</sup> and Coonrad-Morrey<sup>27,38</sup> have been reported as 64%,  
213 67%, 50–92% and 60-100%, respectively. Overall the patient satisfaction rate for our series  
214 was 94% with 63% of patients reporting maximal satisfaction (Very Satisfied). A study of  
215 different linked prostheses (11 elbows) reported a 73% satisfaction rate.<sup>40</sup> In a study of 51  
216 elbows using the Coonrad-Morrey prosthesis, Hildebrand et al,<sup>20</sup> reported patient satisfaction

217 of 9.2/10 in inflammatory arthritis and 8.6/10 in posttraumatic arthritis. A recent study of  
218 Discovery Elbow replacement patients in 46 elbows reported a patient satisfaction rate of  
219 9.1/10 based on modified American Shoulder and Elbow Surgeons elbow score.<sup>18</sup> The study,  
220 however, involved only primary TEAs with majority of them (50%) diagnosed with RA.

221

222 Functional capacity was markedly improved in our cohort of patients according to the LES  
223 which integrates both patient self-evaluation and clinician's assessments. The LES is a more  
224 recently developed elbow-specific outcome measure and less frequently used compared to the  
225 MEPS in TEA studies. However, it has high responsiveness to the changes following TEA<sup>42</sup>  
226 and scored higher (9 of 10) than MEPS (6 of 10) against the strength criteria of an outcome  
227 measure (Content, Methodology, and Clinical Utility) outlined in the AO Handbook  
228 Musculoskeletal Outcomes Measures and Instruments.<sup>39</sup> Furthermore, a strong correlation  
229 exists between LES and MEPS<sup>4</sup> indicating that marked improvement found for the LES in the  
230 present study are in line with those reported for other prostheses.<sup>2,25,27,28,32</sup> The mean  
231 improvement in flexion-extension arc in our TEA series was 21°. Based on systematic  
232 reviews of semiconstrained linked and unlinked TEA prostheses, the average improvement in  
233 flexion-extension arc ranged between 12°-39° with a weighted improvement of 26°.<sup>27,41</sup>  
234 According to individual studies, the mean improvement in flexion-extension arc with  
235 Acclaim,<sup>6</sup> Souter-Strathclyde,<sup>33</sup> GSB III,<sup>21,23</sup> and Coonrad-Morrey prostheses<sup>38</sup> were 23°, 15°,  
236 19°-33° and 17°-26°, respectively. A recent study of 46 Discovery elbows reported an  
237 improvement of 40° in flexion-extension arc.<sup>18</sup> The mean improvement in pronation-  
238 supination arc in our series was 25°. This movement arc has been reported as 21°-28° for  
239 Coonrad-Morrey prosthesis<sup>38</sup> and 31°-67° for GSB III prosthesis.<sup>21,23</sup> Hastings et al,<sup>18</sup>  
240 reported an increase of 29° in pronation-supination arc with Discovery elbow. It has to be  
241 taken into consideration that our reported results combine both primary and revision TEAs.

242

243 Deep infection remains the most worrying complication with a rate of around 4% infection  
244 reported in longer-term TEA studies.<sup>9,27</sup> The overall incidence of deep infection in our series  
245 was 2%. The incidence of deep infection with GSB III TEA has varied between 4%-  
246 11%.<sup>15,23,36</sup> Studies on Coonrad-Morrey TEA have reported an infection incidence rate of  
247 6%-8%.<sup>20,27</sup> Hastings et al,<sup>18</sup> recently summarised complications for Coonrad-Morrey, GSB  
248 III, Solar, and Discovery prostheses in 595 TEA patients (561 primary, 34 revision) and cited  
249 the average rate of deep infection as 2.9%.

250

251 While rates of aseptic loosening appears to have improved to less than 10%,<sup>42</sup> it remains a  
252 major cause of revision following TEA. Progressive aseptic loosening requiring revision  
253 occurred in 4 primary (5%) and 3 revision (12%) patients of our series. In primary group,  
254 humeral and ulnar components were affected in three and one cases, respectively. In revision  
255 group both components were affected. Six of aseptic loosening cases underwent revision  
256 surgery with Discovery elbow and remained stable by the time of final follow-up, one case is  
257 awaiting revision. This complication has been reported in association with other linked  
258 prostheses including Coonrad-Morrey (0%-7%),<sup>1,14,16,20,27</sup> GSB III (4%-29%),<sup>8,15,21,36</sup> and  
259 Souter-Strathclyde (up to 31%).<sup>16,25,32</sup> Summarising the complication reports from linked  
260 devices, Hastings et al,<sup>18</sup> and Kelly et al,<sup>23</sup> have cited the average rate of primary aseptic  
261 loosening as 8.9% and 4%-50%, respectively. In a recently published study of 46 Discovery  
262 elbow cases, aseptic loosening of the humeral component developed in 1 patient (2.2%)  
263 without need to revision.<sup>18</sup> The study however, reported revision of a severe loosening case of  
264 humeral component together with associated condyles and bearing in another patient who did  
265 not meet study population inclusion criteria. Another study of Discovery elbow (18 cases)  
266 reported an aseptic loosening (5.6%) due to inadequate cementing of the ulnar component 17  
267 months following TEA which required revision surgery.<sup>10</sup>

268

269 The overall rate of periprosthetic fracture was 14.8% (primary, 6.8%; revision, 8%) in the  
270 present study. All fractures were classified as Mayo Type 1 and required conservative  
271 management. The incidence of periprosthetic fractures with Acclaim,<sup>6</sup> GSB III,<sup>21,36</sup> and  
272 Coonrad-Morrey<sup>20</sup> has been reported as 36%, 16%-21%, and 23%, respectively.

273

274 Incidence of persistent ulnar neuropathy requiring surgical intervention was 3% in our series.  
275 Ulnar neuropathy is seen more commonly in rheumatoid arthritis as close proximity of the  
276 nerve to the elbow joint can lead to inflammation of the nerve due to synovitis in the nearby  
277 elbow joint and valgus instability can lead to stretching of the ulnar nerve.<sup>29</sup> The incidence  
278 rate of ulnar neuropathy with GSB III, Coonrad-Morrey, and Acclaim has been reported as  
279 11%-14%,<sup>8,23</sup> 12%-26%,<sup>1,20</sup> and 8%,<sup>6</sup> respectively. Summarising the complications of TEA in  
280 595 patients, Hastings et al,<sup>18</sup> cited a rate of 4.4% for ulnar neuropathy.

281

282 The present study provided comprehensive prospective clinical outcome data on for the  
283 Discovery elbow arthroplasty. The study included a large cohort of primary and revision  
284 TEAs which reduced the scope of selection bias. Furthermore, performing clinical and  
285 radiographic assessments by independent assessors decreased the possibility of information  
286 bias. There were, however, some limitations to the study. First, study included both primary  
287 and revision TEAs which might have some effect on reported outcome results. In order to  
288 address this, significant differences between primary and revision TEAs in outcome measures  
289 (e.g. LES) and complications rates are highlighted in the paper. Second, study used LES as a  
290 key functional assessment tool. This reduced the scope of comparisons with other studies into  
291 some extent as based around half of recent outcome reports used MEPS.<sup>27</sup> Hence, MEPS was  
292 added into our functional assessment tools a few years ago and being completed in addition  
293 to LES for all prospective TEAs. Third, a 4-year mean follow-up provides a relatively

- 294 reasonable period for functional outcome report but a longer term follow-up is required for  
295 assessing late complications and survivorship of the prosthesis.

296 **CONCLUSION**

297 The results indicate that Discovery elbow is a system viable option for the treatment of  
298 advanced inflammatory and non-inflammatory elbow conditions where a TEA is indicated.

299 This was reflected in significant improvements in LES, range of movement, pain experience,  
300 and a high patient satisfaction score at a 4-year mean follow-up. The incidence of  
301 complications was either comparable or less than that reported for other linked prostheses.

302 We need to wait for the long term results of this prosthesis to assess its survivorship.



303 **References**

- 304 1. Aldridge JM, Lightdale NR, Mallon WJ, Coonrad RW. Total elbow arthroplasty with the  
305 Coonrad/Coonrad-Morrey prosthesis. A 10- to 31-year survival analysis. *J Bone Joint*  
306 *Surg Br.* 2006; 88:509-14. 10.1302/0301-620X.88B4.17095.
- 307 2. Amirfeyz R, Blewitt N. Mid-term outcome of GSB-III total elbow arthroplasty in  
308 patients with rheumatoid arthritis and patients with post-traumatic arthritis. *Arch Orthop*  
309 *Trauma Surg.* 2009; 129:1505-10. 10.1007/s00402-009-0876-y.
- 310 3. Angst F, John M, Pap G, Mannion AF, Herren DB, Flury M et al. Comprehensive  
311 assessment of clinical outcome and quality of life after total elbow arthroplasty. *Arthritis*  
312 *Rheum* 2005; 53:73-82. 10.1002/art.20911.
- 313 4. Ashmore AM, Gozzard C, Blewitt N. Use of the Liverpool Elbow Score as a postal  
314 questionnaire for the assessment of outcome after total elbow arthroplasty. *J Shoulder*  
315 *Elbow Surg.* 2007; 16:S55-8. 10.1016/j.jse.2006.08.008.
- 316 5. Banagan KE, Murthi AM. Current concepts in total elbow arthroplasty. *Curr Opin*  
317 *Orthop* 2006; 17:335-39 10.1097/01.bco.0000233729.71880.dc.
- 318 6. Bassi RS, Simmons D, Ali F, Nuttall D, Birch A, Trail IA et al. Early results of the  
319 Acclaim elbow replacement. *J Bone Joint Surg Br.* 2007; 89:486-9. 10.1302/0301-  
320 620X.89B4.18197.
- 321 7. Bernardino S. Total elbow arthroplasty: history, current concepts, and future. *Clin*  
322 *Rheumatol.* 2010; 29:1217-21. 10.1007/s10067-010-1539-7.
- 323 8. Cesar M, Roussanne Y, Bonnel F, Canovas F. GSB III total elbow replacement in  
324 rheumatoid arthritis. *J Bone Joint Surg Br.* 2007; 89:330-4. 10.1302/0301-  
325 620X.89B3.18488.

- 326 9. Chafik D, Lee TQ, Gupta R. Total elbow arthroplasty: current indications, factors  
327 affecting outcomes, and follow-up results. *Am J Orthop (Belle Mead NJ)*. 2004; 33:496-  
328 503.
- 329 10. Corradi M, Frattini M, Panno B, Tocco S, Pogliacomì F. Linked semi-constrained total  
330 elbow prosthesis in chronic arthritis: results of 18 cases. *Musculoskelet Surg*. 2010; 94  
331 Suppl 1:S11-23. 10.1007/s12306-010-0070-y.
- 332 11. Figgie MP. Anatomy, Biomechanics, and Kinematics of Total Elbow Replacement. In:  
333 R  ther W, editor. *The Elbow*: Springer Berlin Heidelberg; 1996, p. 20-34. (ISBN No.  
334 978-3-642-79741-5)
- 335 12. Figgie MP, Su EP, Kahn B, Lipman J. Locking mechanism failure in semiconstrained  
336 total elbow arthroplasty. *J Shoulder Elbow Surg*. 2006; 15:88-93.  
337 10.1016/j.jse.2005.05.007.
- 338 13. Futai K, Tomita T, Yamazaki T, Murase T, Yoshikawa H, Sugamoto K. In vivo three-  
339 dimensional kinematics of total elbow arthroplasty using fluoroscopic imaging. *Int*  
340 *Orthop*. 2010; 34:847-54. 10.1007/s00264-010-0972-1.
- 341 14. Gill DR, Morrey BF. The Coonrad-Morrey total elbow arthroplasty in patients who have  
342 rheumatoid arthritis. A ten to fifteen-year follow-up study. *J Bone Joint Surg Am*. 1998;  
343 80:1327-35.
- 344 15. Gschwend N, Scheier NH, Baehler AR. Long-term results of the GSB III elbow  
345 arthroplasty. *J Bone Joint Surg Br*. 1999; 81:1005-12.
- 346 16. Guttler K, Landor I, Vavrik P, Popelka S, Sosna A, Krasensky J. Total elbow  
347 replacement in patients with rheumatoid arthritis. *Acta Chir Orthop Traumatol Cech*.  
348 2011; 78:423-30.
- 349 17. Hastings H. Minimally constrained elbow implant arthroplasty: the discovery elbow  
350 system. *Tech Hand Up Extrem Surg*. 2004; 8:34-50.

- 351 18. Hastings H, Lee DH, Pietrzak WS. A prospective multicenter clinical study of the  
352 Discovery elbow. *J Shoulder Elbow Surg.* 2014; 23:e95-e107. 10.1016/j.jse.2013.12.033.
- 353 19. Hastings H, Theng CS. Total elbow replacement for distal humerus fractures and  
354 traumatic deformity: results and complications of semiconstrained implants and design  
355 rationale for the Discovery Elbow System. *Am J Orthop (Belle Mead NJ).* 2003; 32:20-8.
- 356 20. Hildebrand KA, Patterson SD, Regan WD, MacDermid JC, King GJ. Functional  
357 outcome of semiconstrained total elbow arthroplasty. *J Bone Joint Surg Am.* 2000; 82-  
358 A:1379-86.
- 359 21. Jensen CH, Jacobsen S, Ratchke M, Sonne-Holm S. The GSB III elbow prosthesis in  
360 rheumatoid arthritis: a 2- to 9-year follow-up. *Acta Orthop.* 2006; 77:143-8.  
361 10.1080/17453670610045830.
- 362 22. Kamineni S, Morrey BF. Distal humeral fractures treated with noncustom total elbow  
363 replacement. Surgical technique. *J Bone Joint Surg Am.* 2005; 87 Suppl 1:41-50.  
364 10.2106/JBJS.D.02871.
- 365 23. Kelly EW, Coghlan J, Bell S. Five- to thirteen-year follow-up of the GSB III total elbow  
366 arthroplasty. *J Shoulder Elbow Surg.* 2004; 13:434-40. 10.1016/S105827460400045X.
- 367 24. King GJ. New frontiers in elbow reconstruction: total elbow arthroplasty. *Instr Course*  
368 *Lect.* 2002; 51:43-51.
- 369 25. Landor I, Vavrik P, Jahoda D, Guttler K, Sosna A. Total elbow replacement with the  
370 Souter-Strathclyde prosthesis in rheumatoid arthritis. Long-term follow-up. *J Bone Joint*  
371 *Surg Br.* 2006; 88:1460-3. 10.1302/0301-620x.88b11.17807.
- 372 26. Lee BP, Adams RA, Morrey BF. Polyethylene wear after total elbow arthroplasty. *J*  
373 *Bone Joint Surg Am.* 2005; 87:1080-7. 10.2106/JBJS.D.02163.

- 374 27. Little CP, Graham AJ, Karatzas G, Woods DA, Carr AJ. Outcomes of total elbow  
375 arthroplasty for rheumatoid arthritis: comparative study of three implants. *J Bone Joint*  
376 *Surg Am.* 2005; 87:2439-48. 10.2106/JBJS.D.02927.
- 377 28. Maheshwari R, Vaziri S, Helm RH. Total elbow replacement with the Coonrad-Morrey  
378 prosthesis: our medium to long-term results. *Ann R Coll Surg Engl.* 2012; 94:189-92.  
379 10.1308/003588412x13171221589775.
- 380 29. Mansat P. Surgical treatment of the rheumatoid elbow. *Joint Bone Spine.* 2001; 68:198-  
381 210.
- 382 30. O'Driscoll SW, Morrey BF. Periprosthetic fractures about the elbow. *Orthop Clin North*  
383 *Am.* 1999; 30:319-25.
- 384 31. Petscavage JM, Ha AS, Chew FS. Radiologic review of total elbow, radial head, and  
385 capitellar resurfacing arthroplasty. *Radiographics* 2012; 32:129-49.  
386 10.1148/rg.321105733.
- 387 32. Prasad N, Dent C. Outcome of total elbow replacement for rheumatoid arthritis: single  
388 surgeon's series with Souter-Strathclyde and Coonrad-Morrey prosthesis. *J Shoulder*  
389 *Elbow Surg.* 2010; 19:376-83. 10.1016/j.jse.2009.09.016.
- 390 33. Rozing P. Souter-Strathclyde total elbow arthroplasty. *J Bone Joint Surg Br.* 2000;  
391 82:1129-34.
- 392 34. Sanchez-Sotelo J. Total elbow arthroplasty. *Open Orthop J.* 2011; 5:115-23.  
393 10.2174/1874325001105010115.
- 394 [REDACTED]
- 395 [REDACTED]
- 396 [REDACTED]
- 397 36. Schneeberger AG, Hertel R, Gerber C. Total elbow replacement with the GSB III  
398 prosthesis. *J Shoulder Elbow Surg.* 2000; 9:135-9.

- 399 37. Seitz WH, Jr., Bismar H, Evans PJ. Failure of the hinge mechanism in total elbow  
400 arthroplasty. *J Shoulder Elbow Surg.* 2010; 19:368-75. 10.1016/j.jse.2009.11.004.
- 401 38. Shi LL, Zurakowski D, Jones DG, Koris MJ, Thornhill TS. Semiconstrained primary and  
402 revision total elbow arthroplasty with use of the Coonrad-Morrey prosthesis. *J Bone*  
403 *Joint Surg Am.* 2007; 89:1467-75. 10.2106/JBJS.F.00715.
- 404 39. Suk M, Hanson BP, Norvell DC, Helfet DL. AO handbook of outcomes measures and  
405 instruments. . In. New York: Thieme Medical Publisher; 2005; 142-7.
- 406 40. Surgical Technique for Discovery™ Elbow System.
- 407 41. <http://www.rcsed.ac.uk/fellows/lvanrensburg/classification/surgtech/biomet/manuals/disc>  
408 [covery%20total%20elbow.pdf](http://www.rcsed.ac.uk/fellows/lvanrensburg/classification/surgtech/biomet/manuals/disc). Last accessed on 22/07.2014.
- 409 42. van der Lugt JC, Rozing PM. Systematic review of primary total elbow prostheses used  
410 for the rheumatoid elbow. *Clin Rheumatol.* 2004; 23:291-8. 10.1007/s10067-004-0884-9.
- 411 [REDACTED]
- 412 [REDACTED]
- 413 [REDACTED]
- 414 44. Voloshin I, Schippert DW, Kakar S, Kaye EK, Morrey BF. Complications of total elbow  
415 replacement: a systematic review. *J Shoulder Elbow Surg.* 2011; 20:158-68.  
416 10.1016/j.jse.2010.08.026.
- 417 45. Wright TW, Hastings H. Total elbow arthroplasty failure due to overuse, C-ring failure,  
418 and/or bushing wear. *J Shoulder Elbow Surg.* 2005; 14:65-72. 10.1016/j.jse.2004.04.015.

419 **Figure and Table Legends**

420 **Figure1.** Lateral and anteroposterior x-rays of an elbow with osteoarthritis before (a-b) and  
421 6-year after total elbow arthroplasty with Discovery Elbow (c-d).

422 **Figure2.** Graphic illustration of the Mayo Clinic classification system used for describing  
423 periprosthetic fractures in elbow arthroplasty. It is important to differentiate between different  
424 types of fractures as those affecting the hardware stems (types 2 and 3) will potentially  
425 require revision. (Reprinted with permission from RadioGraphics.<sup>31</sup>

426 **Table1.** Incidence of diagnoses for primary and revision Total Elbow Arthroplasty (TEA)

427 **Table2.** Comparison of the mean (SD) pre- and postoperative elbow and forearm ROM with  
428 Discovery Elbow according to main underlying pathologies in all patients (primary and  
429 revision)

430 **Table3.** Prosthesis alignment in primary and revision Total Elbow Arthroplasty (TEA)

**Table1.** Incidence of diagnoses for primary and revision Total Elbow Arthroplasty (TEA)

<b>Main Diagnoses and sub-diagnoses</b>	<b>Incidence (%) (n = 100 elbows)</b>
<b>Inflammatory Arthritis</b>	
Rheumatoid Arthritis	54
Juvenile Rheumatoid Arthritis	2
Psoriatic Arthritis	2
<b>Non-Inflammatory Arthritis</b>	
Degenerative Osteoarthritis	17
Traumatic Arthritis	14
Haemophilic Arthropathy	3
Nail-patella syndrome	1
<b>Distal Humerus Fracture (acute and non-union)</b>	7
<b>Total TEA</b>	<b><u>100</u></b>
<b>Revision TEA</b>	
Inflammatory Arthritis	16
Non-Inflammatory Arthritis	7
Fracture	2
<b>Total</b>	<b><u>25</u></b>

**Table2.** Comparison of the mean (SD) pre- and postoperative elbow and forearm ROM with Discovery Elbow according to main underlying pathologies in all patients (primary and revision)

Elbow/Forearm ROM	All Patients		Non-Inflammatory (Osteoarthritis)		Inflammatory (Rheumatoid Arthritis)		Fracture	
	Pre-op	Post-op	Pre-op	Post-op	Pre-op	Post-op	Pre-op	Post-op
Flexion	100 (24)	118 (17)**	101 (26)	118 (18) *	100 (20)	117 (16)**	92 (38)	115 (28)
Extension lag	28 (14)	25 (14)	28 (11)	25 (12)	28 (16)	26 (16)	23 (15)	18 (17)
FLX-EXT ARC	72 (28)	93 (27)**	73 (30)	93 (26)*	72 (27)	92 (26)**	87 (33)	97 (44)
Pronation	48 (23)	61 (21)**	49 (25)	64 (18)*	46 (23)	59 (22)*	61 (17)	64 (15)
Supination	38 (26)	50 (25)**	42 (26)	55 (21)*	35 (26)	45 (25)*	52 (23)	51 (29)
PRON-SUP ARC	86 (45)	111 (42)**	91 (48)	119 (35)**	81 (44)	104 (42)*	113 (39)	115 (41)

-SD, Standard Deviation; FLX, Flexion; EXT, Extension; ROM, Range of Motion; Pre-op, Preoperative; Post-op, Postoperative.

-Significant difference at  $P \leq .05$  (\*) and  $P \leq .001$  (\*\*).



**Table3.** Prosthesis alignment in primary and revision Total Elbow Arthroplasty (TEA)

Degree of Malalignment	Coronal Plane		Sagittal Plane	
	Humerus	Ulna	Humerus	Ulna
<b>PRIMARY TEA</b>				
Less than 5 degrees	61	57	48	63
5-10 degrees	9	13	22	6
More than 10 degrees	0	0	0	1
<b>REVISION TEA</b>				
Less than 5 degrees	16	16	14	17
5-10 degrees	2	2	4	1
More than 10 degrees	0	0	0	0




**TYPE 3**

**TYPE 2**

**TYPE 3**

**TYPE 1**

**FRACTURE TYPES**



## **Figure and Table Legends**

**Figure1.** Lateral and anteroposterior x-rays of an elbow with osteoarthritis before (a-b) and 6-year after total elbow arthroplasty with Discovery Elbow (c-d).

**Figure2.** Graphic illustration of the Mayo Clinic classification system used for describing periprosthetic fractures in elbow arthroplasty. It is important to differentiate between different types of fractures as those affecting the hardware stems (types 2 and 3) will potentially require revision. (Reprinted with permission from RadioGraphics.<sup>29</sup>)

**Table1.** Incidence of diagnoses for primary and revision TEA

**Table2.** Comparison of pre- and postoperative elbow and forearm range of motion with Discovery Elbow according to main underlying pathologies in all patients (primary and revision)

**Table3.** Prosthesis alignment in primary and revision TEA

## Liverpool elbow score

	Score 4	Score 3	Score 2	Score 1	Score 0
Clinical assessment					
1. Flexion	-	>135°	120-135°	90-120°	<90°
2. Extension	-	None	<20°	20-30°	>30°
3. Pronation (add 1 to score if wrist/forearm pathology)	-	-	>50°	50-20°	<20°
4. Supination (add 1 to score if wrist/forearm pathology)	-	-	>50°	50-20°	<20°
5. Strength: average of flexion, extension, pronation and supination	Apparently normal	Complete motion against gravity and some resistance	Complete motion against gravity	Complete motion with gravity eliminated	Absent
6. Ulnar nerve	-	None	Sensory	Motor: no disability	Motor: With disability
Patient-answered question During the past four weeks:					
1. How often have you had to use your other arm to do things normally done by the affected arm?	Never	Once or twice	Sometime	Many times	Every time
2. Has your elbow problem caused you any difficulty in combing your hair?	None	Little	Moderate	Severe	Unable to do
3. Has your elbow problem caused you any difficulty in washing yourself?	None	Little	Moderate	Severe	Unable to do
4. Has your elbow problem caused you any difficulty in feeding yourself?	None	Little	Moderate	Severe	Unable to do
5. Has your elbow problem caused you any difficulty in dressing yourself?	None	Little	Moderate	Severe	Unable to do
6. Has your elbow problem caused you any difficulty in trying to do household activities?	None	Little	Moderate	Severe	Unable to do
7. Has your elbow problem caused you any difficulty in lifting, e.g. a kettle, a milk bottle, groceries?	None	Little	Moderate	Severe	Unable to do
8. How would you describe the pain from this elbow?	None	Little	Moderate	Severe	Unbearable
9. Has your elbow problem affected your sport and leisure activities?	None	Little	Moderate	Severe	Unable to do